SCHEMBL3507948

SCHEMBL3507948

O=c1ccn(-c2cccnc2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.51
HTT P42858 2/20 0.46
CYP3A4 P08684 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
EP300 Q09472 1/20 0.44
KAT2B Q92831 1/20 0.44
MTOR P42345 3/20 0.43
CYP11B2 P19099 2/20 0.43
CYP2E1 P05181 1/20 0.42
ELANE P08246 1/20 0.41
RPTOR Q8N122 1/20 0.41
MLST8 Q9BVC4 1/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41
HSD17B10 Q99714 2/20 0.41
MAPK1 P28482 1/20 0.41
AR P10275 1/20 0.41
ALDH1A1 P00352 1/20 0.40
RECQL P46063 1/20 0.40
CYP11B1 P15538 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9613892 0.81 HPGDS (0.47) HTTL3MBTL1MTORRPTORMLST8
SCHEMBL3781054 0.79 BCHE (0.41) EP300KAT2BMTORMAPK1AR
SCHEMBL246203 0.77 CYP2A6 (0.58) CYP2A6HTTCYP3A4EP300KAT2B
SCHEMBL31554123 0.77 CYP2A6 (0.58) CYP2A6HTTCYP3A4EP300KAT2B
SCHEMBL30241908 0.76 CYP2A6 (0.58) CYP2A6HTTCYP3A4L3MBTL1EP300
SCHEMBL3507072 0.72 CYP19A1 (0.51) CYP11B2MAPTALDH1A1CYP11B1
SCHEMBL12410587 0.72 CYP2A6 (0.56) CYP2A6HTTCYP3A4L3MBTL1MTOR
SCHEMBL14889183 0.71 ALDH1A1 (0.44) HTTGAAMAPTALDH1A1
SCHEMBL12004826 0.70 CYP2A6 (0.55) CYP2A6HTTCYP3A4EP300KAT2B
SCHEMBL3505817 0.70 NCOA3 (0.50) HTTCYP11B2GAAMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187455-B2 Substituted pyridazines as PDE10A inhibitors HOFFMANN-LA ROCHE INC. (US) 2015-11-17 US disclosed
US-20100216793-A1 HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216793-A1 HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES PDE3A, PDE10A, PDE5A CYP2A6 129/4885HTT 4266/4885CYP3A4 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.